Laryngeal Cryotherapy for Refractory Neurogenic Cough

Description

This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure

Conditions

Upper-Airway Cough Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure

To Determine the Efficacy of Topical Cryotherapy on Supraglottic Laryngeal Mucosa in the Treatment of Chronic Neurogenic Cough in Adult Patients

Laryngeal Cryotherapy for Refractory Neurogenic Cough

Condition
Upper-Airway Cough Syndrome
Intervention / Treatment

-

Contacts and Locations

Dallas

UT Southwestern Medical Center, Dallas, Texas, United States, 75235

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients 18 years or older with diagnosis of neurogenic cough
  • * Neurogenic cough is a diagnosis of exclusion applied to persistent cough (8 weeks or longer)
  • * Negative workup for other causes, including sinonasal allergies/chronic sinusitis, cough-variant asthma, and GERD
  • * Patient willing to participate in a clinical trial
  • * Uncontrolled reflux (scoring on Reflux Symptom index of 13 or higher)
  • * Vocal fold abnormalities or impairment
  • * History of asthma or other underlying lung condition not adequately treated or controlled
  • * Uncontrolled Allergic Rhinitis (Total Nasal Symptom Score \>6, which would indicate moderate disease32)
  • * Reported symptom of postnasal drip
  • * Current smoker
  • * Current neuromodulator medication use
  • * Patient unwilling to participate in clinical trial or sign an informed consent
  • * End stage medical disease with poor life expectancy
  • * Medical instability deemed by the investigators as a contraindication for enrollment
  • * Abnormal Chest X-ray
  • * Abnormal pulmonary function testing (PFTs)
  • * Positive local allergy panel (combined RAST testing)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Texas Southwestern Medical Center,

Study Record Dates

2024-12-30